Illumina (XSWX:ILMN) Moat Score: 8/10 (As of Jun. 27, 2026)


XSWX:ILMN Illumina Inc XSWX:ILMN
76 GF Score
Price CHF143.95
GF Value CHF105.51
! 7 Warning Signs
View Full Analysis

What is Illumina Moat Score?

Illumina XSWX:ILMN -0.79% 76 Moat Score is 8 as of Jun. 27, 2026. GuruFocus rates XSWX:ILMN with a GF Score™ of 76/100 and a GF Value™ of CHF105.51. The stock has 7 warning signs investors should review. Among 217 Medical Diagnostics & Research companies, Illumina ranks better than 99.08% on this metric.

Illumina has the Moat Score of 8, which implies that the company might have Wide Moat - Clear and robust wide moat.

Illumina has Wide Moat: Illumina Inc has a robust wide moat due to its market leadership in genomic sequencing, strong intellectual property, significant customer switching costs, and consistent innovation.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Illumina might have Wide Moat - Clear and robust wide moat.

Illumina  (XSWX:ILMN) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Illumina Moat Score Related Terms

XSWX:ILMN vs MTD, DGX, LH: Moat Score Comparison

For the Diagnostics & Research subindustry, Illumina's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Illumina Moat Score vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Illumina's Moat Score distribution charts can be found below:

* The bar in red indicates where Illumina's Moat Score falls into.


XSWX:ILMN
76GF Score
Illumina Inc XSWX:ILMN
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 8 mean?
Illumina (XSWX:ILMN) has a Moat Score of 8 as of Jun. 27, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Illumina ranks #2 out of 217 companies in the Medical Diagnostics & Research industry, placing it in the top 0.90000000000001%.
Is Illumina's Moat Score too high?
Illumina's current Moat Score is 8. Based on the distribution chart, Illumina ranks #2 out of 217 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Illumina has a GF Score™ of 76/100, reflecting its overall financial health beyond just this single metric.
How does Illumina's Moat Score compare to MTD and DGX?
According to the Medical Diagnostics & Research industry distribution chart, Illumina ranks #2 out of 217 companies for Moat Score. This places Illumina in the top 1% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Medical Diagnostics & Research company?
A good Moat Score depends on the Medical Diagnostics & Research industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Illumina's current Moat Score is 8. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Illumina stock overvalued right now?
Illumina (XSWX:ILMN) has a current Moat Score of 8. The stock's GF Value™ is CHF105.51, compared to a current price of CHF143.95 — trading 36.4% above its estimated fair value. The current Moat Score is 8. Illumina's overall GF Score™ is 76/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Illumina (XSWX:ILMN), the current Moat Score is 8 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Illumina (XSWX:ILMN) Overvalued in 2026?

Based on GuruFocus' analysis, Illumina stock appears to be overvalued. The current stock price of CHF143.95 is trading 36.4% above its estimated GF Value™ of CHF105.51.

Key valuation signals for XSWX:ILMN:

  • Moat Score: 8
  • GF Value™: CHF105.51 vs. price of CHF143.95 (36.4% above fair value)
  • GF Score™: 76/100 with 7 warning signs

No single metric tells the full story. See the XSWX:ILMN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Illumina Business Description

Address 5200 Illumina Way, San Diego, CA, USA, 92122
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
76GF Score

Get the complete analysis for XSWX:ILMN

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF143.95
Price
CHF105.51
GF Value